Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13791869 | 1.00 | FYN (0.35) | FYNALDH1A1L3MBTL3L3MBTL1HTR6 | |
| SCHEMBL12038515 | 0.97 | ALDH1A1 (0.35) | FYNALDH1A1L3MBTL3L3MBTL1HTR6 | |
| SCHEMBL18136222 | 0.92 | — | — | |
| SCHEMBL18035317 | 0.91 | FYN (0.31) | FYNALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL24185469 | 0.85 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL8272492 | 0.82 | ALDH1A1 (0.43) | ALDH1A1L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL8438291 | 0.82 | ALDH1A1 (0.43) | ALDH1A1L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL8374383 | 0.82 | ALDH1A1 (0.43) | ALDH1A1L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL8272489 | 0.82 | ALDH1A1 (0.43) | ALDH1A1L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL8439289 | 0.82 | ALDH1A1 (0.43) | ALDH1A1L3MBTL3L3MBTL1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2022253250-A1 | BRUTON'S TYROSINE KINASE DEGRADER CONTAINING FUSED-RING OR SPIRO-RING | 正大天晴药业集团股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2021180235-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | 四川海思科制药有限公司 | 2021-09-16 | — | — | WO | disclosed |
| WO-2021129820-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | 微境生物医药科技(上海)有限公司 | 2021-07-01 | — | — | WO | disclosed |
| US-20210154178-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-10952996-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3680237-A1 | PROCESS FOR PREPARING SUBSTITUTED 2,3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | Arrien Pharmaceuticals LLC (US) | 2020-07-15 | — | — | EP | disclosed |
| WO-2020123453-A2 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-7547692-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS PHARMA, LLC (US) | 2009-06-16 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20070155715-A1 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070142392-A1 | Uses of rifamycins | ACTIVBIOTICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952996-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | FYN 1350/4885ALDH1A1 3284/4885L3MBTL3 1287/4885 |
| US-20070142392-A1 | Uses of rifamycins | TNF, TLR6, IL6 | FYN 2461/4885ALDH1A1 1604/4885L3MBTL3 3521/4885 |
| US-20210154178-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | FYN 1350/4885ALDH1A1 3284/4885L3MBTL3 1287/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | FYN 1350/4885ALDH1A1 3284/4885L3MBTL3 1287/4885 |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | KCNT1, KCNMA1, KCNJ2 | FYN 2105/4885ALDH1A1 2383/4885L3MBTL3 1992/4885 |
| US-20070155715-A1 | Rifamycin analogs and uses thereof | RIF1, FNTB, MRPL21 | FYN 4403/4885ALDH1A1 2111/4885L3MBTL3 1403/4885 |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | FYN 147/4885ALDH1A1 975/4885L3MBTL3 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.